nach oben

Breast Cancer Research

Erschienen in:

01.02.2006 | Letter

The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction

verfasst von: Alberto Pinzon-Charry, Chris W Schmidt, José Alejandro López

Erschienen in: Breast Cancer Research | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy against breast cancer. CD40 ligand (CD40L), a key molecule in the interface between T-lymphocytes and DCs, seems to be instrumental in achieving that goal. Commenting on our data that CD40L protects circulating DCs from apoptosis induced by breast tumor products, Lenahan and Avigan highlighted the potential of CD40L for immunotherapy. We expand on that argument by pointing to additional findings that CD40L not only rescues genuine DCs but also functionally improves populations of immature antigen-presenting cells that fill the DC compartment in patients with breast cancer.

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol. 2000, 18: 767-811. 10.1146/annurev.immunol.18.1.767.CrossRefPubMed

Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998, 393: 480-483. 10.1038/31002.CrossRefPubMed

Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-killer cell. Nature. 1998, 393: 474-478. 10.1038/30989.CrossRefPubMed

Pinzon-Charry A, Maxwell T, McGuckin MA, Schmidt C, Furnival C, Lopez JA: Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res. 2006, 8: R5-10.1186/bcr1361.CrossRefPubMed

Lenahan C, Avigan D: Dendritic cell defects in patients with cancer: mechanisms and significance. Breast Cancer Res. 2006, 8: 101-10.1186/bcr1375.CrossRefPubMedPubMedCentral

Terheyden P, Straten P, Brocker EB, Kampgen E, Becker JC: CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-γ-producing T cells from tumor-infiltrating lymphocytes. J Immunol. 2000, 164: 6633-6639.CrossRefPubMed

Lopez JA, Hart DN: Current issues in dendritic cell cancer immunotherapy. Curr Opin Mol Ther. 2002, 4: 54-63.PubMed

Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med. 2004, 10: 475-480. 10.1038/nm1039.CrossRefPubMed

Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, et al: Dendritic cells are functionally defective in multiple myeloma: the role of inter-leukin-6. Blood. 2002, 100: 230-237. 10.1182/blood.V100.1.230.CrossRefPubMed

10.

Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997, 3: 483-490.PubMed

11.

Pinzon-Charry A, Ho C, Laherty R, Maxwell T, Walker D, Gardiner R, O'Connor L, Pyke C, Schmidt CW, Furnival C, et al: A population of HLA-DR+ immature cells accumulate in the blood den-dritic cell compartment of patients with different types of cancer. Neoplasia. 2005, 7: 1123-1132. 10.1593/neo.05442.CrossRefPubMedPubMedCentral

12.

Pinzon-Charry A, Maxwell T, Prato S, Furnival C, Schmidt CW, Lopez JA: HLA-DR+ immature cells exhibit reduced antigen presenting cell function but respond to CD40 stimulation. Neoplasia. 2005, 7: 1112-1122. 10.1593/neo.05448.CrossRefPubMedPubMedCentral

Titel: The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction
verfasst von: Alberto Pinzon-Charry
Chris W Schmidt
José Alejandro López
Publikationsdatum: 01.02.2006
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 1/2005
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1386

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Springer Medizin

The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction

Abstract

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2005

Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect

Overdiagnosis and overtreatment of breast cancer: Microsimulation modelling estimates based on observed screen and clinical data

Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study

The evolving paradigm of tissue-specific metastasis

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families

Key stages in mammary gland development: The cues that regulate ductal branching morphogenesis

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie